Instruction for use: Binelol

Trade name of the drug – Binelol

Dosage Form: tablets

Active substance:Nebivololum

ATX

C07AB12 Nebivolol

Pharmacotherapeutic group: Beta1-selective blocker [Beta-blockers]

The nosological classification (ICD-10)

I10 Essential (primary) hypertension: hypertension; Arterial hypertension; Arterial hypertension crisis course; Essential Hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Primary hypertension; Arterial hypertension, complications of diabetes; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; arterial Hypertension; malignant Hypertension; Hypertonic disease; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; Isolated systolic hypertension

I15 Secondary hypertension: Arterial hypertension, complications of diabetes; hypertension; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; hypertension; arterial Hypertension; malignant Hypertension; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; hypertension; Arterial hypertension; Arterial hypertension crisis course; renovascular hypertension; Hypertension symptomatic; Renal hypertension; Renovascular hypertension; renovascular hypertension; Symptomatic hypertension

I25.9 Chronic ischemic heart disease, unspecified: CHD; Insufficiency of coronary circulation; Coronary atherosclerosis in patients with coronary artery disease

I50.0 Congestive heart failure: anasarca heart; Decompensated congestive heart failure; Congestive heart failure; Congestive heart failure with high afterload; Congestive chronic heart failure; Cardiomyopathy with severe chronic heart failure; Compensated chronic heart failure; Swelling with circulatory failure; Edema of cardiac origin; Swelling of the heart; Edematous syndrome in diseases of the heart; Edematous syndrome in congestive heart failure; Edematous syndrome in heart failure; Edematous syndrome in heart failure or liver cirrhosis; right ventricular failure; Congestive Heart Failure; Heart failure stagnant; Heart failure with low cardiac output; Heart failure is a chronic; Cardiac edema; Chronic decompensated heart failure; Chronic Congestive Heart Failure; Chronic heart failure; Change of liver function in heart failure

Composition (per tablet):

active substance: Nebivolol (in the form of nebivolol hydrochloride) 5 mg

Excipients: lactose monohydrate - 85.96 mg; crospovidone (type A) - 6,89 mg; Poloxamer 188 - 6.9 mg; povidone K30 - 3.5 mg; MCC - 119 mg; Magnesium stearate - 2.3 mg

Pharmacological Properties of Binelol

Pharmachologic effect - antianginal, antihypertensive, anti-arrhythmic.

Dosage and Administration

Inside, at the same time of the day regardless of the meal, not chewing and drinking plenty of fluids.

Arterial hypertension and coronary heart disease. The average daily dose for the treatment of hypertension and coronary heart disease is 2.5-5 mg (1 / 2-1 table.) 1 times a day. Possible use of the drug in monotherapy or in combination therapy.

In patients with renal insufficiency and in patients older than 65 years of the initial dose is 2.5 mg / day (Table 1/2. 5 mg).

If necessary, the daily dose can be increased to 10 mg (Table 2. 5 mg) in one portion.

Chronic heart failure. Treatment of chronic heart failure should begin with a gradual increase in dose until the optimal individual maintenance dose.

Dose selection at the beginning of treatment should be implemented as follows, and maintaining weekly intervals based on patient tolerability of this dose: the dose is 1.25 mg (. Table 1/4) 1 times a day, can be increased to 2.5 first -5 mg (1 / Table 2.1.) and then - 10 mg (. Table 2) times in one day.

release Form

Tablets of 5 mg. According to Table 14. PVC / PE / PVDC / aluminum blister. 1, or 2, 4 bl. placed in a cardboard box.

Manufacturer

Belupo, medications and cosmetics dd 48000, Koprivnica, ul. Danica, 5.

Produced by: SPETSIFAR SA, Greece.

Primary / secondary packaging and producing quality control: Belupo, medications and cosmetics dd, Croatia.

Representation Belupo, medications and cosmetics dd, the Republic of Croatia in Russia: 119330, Moscow Lomonosov Ave, 38, Apt. 71-72.

Conditions of supply of pharmacies

Storage conditions of Binelol

The temperature is not above 30 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use beyond the expiration date printed on the package.